CI vs DVA: fair value comparison
The Cigna Group and DaVita Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, CI currently sits closer to the top of our discount ranking. DVA carries the stronger quality grade.
| CI | DVA | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $280.76 | $181.55 |
| 12-month range | $244.41–$289.26 | $111.19–$240.09 |
| Sector rank | #39 of 113 Healthcare | #40 of 113 Healthcare |
| Quality grade | F | C |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: CI fair value analysis · DVA fair value analysis